Logo image of VVOS

VIVOS THERAPEUTICS INC (VVOS) Stock Fundamental Analysis

NASDAQ:VVOS - Nasdaq - US92859E2072 - Common Stock - Currency: USD

3.12  -0.17 (-5.17%)

After market: 3.15 +0.03 (+0.96%)

Fundamental Rating

3

Taking everything into account, VVOS scores 3 out of 10 in our fundamental rating. VVOS was compared to 108 industry peers in the Health Care Providers & Services industry. While VVOS seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, VVOS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VVOS had negative earnings in the past year.
In the past year VVOS has reported a negative cash flow from operations.
In the past 5 years VVOS always reported negative net income.
VVOS had a negative operating cash flow in each of the past 5 years.
VVOS Yearly Net Income VS EBIT VS OCF VS FCFVVOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

VVOS's Return On Assets of -81.89% is on the low side compared to the rest of the industry. VVOS is outperformed by 92.52% of its industry peers.
Looking at the Return On Equity, with a value of -163.97%, VVOS is doing worse than 84.11% of the companies in the same industry.
Industry RankSector Rank
ROA -81.89%
ROE -163.97%
ROIC N/A
ROA(3y)-120.22%
ROA(5y)-110.13%
ROE(3y)-1293.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VVOS Yearly ROA, ROE, ROICVVOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

VVOS's Gross Margin of 60.76% is amongst the best of the industry. VVOS outperforms 82.24% of its industry peers.
In the last couple of years the Gross Margin of VVOS has declined.
VVOS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.05%
GM growth 5Y-3.47%
VVOS Yearly Profit, Operating, Gross MarginsVVOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

5

2. Health

2.1 Basic Checks

VVOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VVOS has more shares outstanding
VVOS has more shares outstanding than it did 5 years ago.
VVOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VVOS Yearly Shares OutstandingVVOS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
VVOS Yearly Total Debt VS Total AssetsVVOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

VVOS has an Altman-Z score of -9.40. This is a bad value and indicates that VVOS is not financially healthy and even has some risk of bankruptcy.
VVOS has a worse Altman-Z score (-9.40) than 90.65% of its industry peers.
There is no outstanding debt for VVOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.4
ROIC/WACCN/A
WACC9.06%
VVOS Yearly LT Debt VS Equity VS FCFVVOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 1.44 indicates that VVOS should not have too much problems paying its short term obligations.
The Current ratio of VVOS (1.44) is comparable to the rest of the industry.
A Quick Ratio of 1.44 indicates that VVOS should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.44, VVOS perfoms like the industry average, outperforming 52.34% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.44
Quick Ratio 1.44
VVOS Yearly Current Assets VS Current LiabilitesVVOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.87% over the past year.
Looking at the last year, VVOS shows a small growth in Revenue. The Revenue has grown by 0.49% in the last year.
VVOS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 29.50% yearly.
EPS 1Y (TTM)55.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.31%
Revenue 1Y (TTM)0.49%
Revenue growth 3Y1.83%
Revenue growth 5Y29.5%
Sales Q2Q%16.93%

3.2 Future

VVOS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.86% yearly.
VVOS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.05% yearly.
EPS Next Y78.98%
EPS Next 2Y37.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.72%
Revenue Next 2Y17.05%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
VVOS Yearly Revenue VS EstimatesVVOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
VVOS Yearly EPS VS EstimatesVVOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15 -20 -25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VVOS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VVOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VVOS Price Earnings VS Forward Price EarningsVVOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VVOS Per share dataVVOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

VVOS's earnings are expected to grow with 37.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.86%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VVOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVOS THERAPEUTICS INC

NASDAQ:VVOS (2/21/2025, 8:00:01 PM)

After market: 3.15 +0.03 (+0.96%)

3.12

-0.17 (-5.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners13.7%
Inst Owner Change-81.64%
Ins Owners1.24%
Ins Owner Change0%
Market Cap18.38M
Analysts82.5
Price Target6.43 (106.09%)
Short Float %5.19%
Short Ratio1.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)39.84%
Min EPS beat(2)35.71%
Max EPS beat(2)43.98%
EPS beat(4)2
Avg EPS beat(4)-3.32%
Min EPS beat(4)-56.97%
Max EPS beat(4)43.98%
EPS beat(8)5
Avg EPS beat(8)10.87%
EPS beat(12)6
Avg EPS beat(12)1.49%
EPS beat(16)6
Avg EPS beat(16)-28.49%
Revenue beat(2)1
Avg Revenue beat(2)1.8%
Min Revenue beat(2)-6.81%
Max Revenue beat(2)10.4%
Revenue beat(4)1
Avg Revenue beat(4)-1.16%
Min Revenue beat(4)-6.81%
Max Revenue beat(4)10.4%
Revenue beat(8)1
Avg Revenue beat(8)-8.34%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.22%
EPS NY rev (1m)0%
EPS NY rev (3m)11.76%
Revenue NQ rev (1m)-16.59%
Revenue NQ rev (3m)-16.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.26
P/FCF N/A
P/OCF N/A
P/B 2.4
P/tB 4.14
EV/EBITDA N/A
EPS(TTM)-5.68
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-2.22
FCFYN/A
OCF(TTM)-2.12
OCFYN/A
SpS2.48
BVpS1.3
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.89%
ROE -163.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.76%
FCFM N/A
ROA(3y)-120.22%
ROA(5y)-110.13%
ROE(3y)-1293.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.05%
GM growth 5Y-3.47%
F-Score5
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.26%
Cap/Sales 3.88%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.44
Quick Ratio 1.44
Altman-Z -9.4
F-Score5
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)198.46%
Cap/Depr(5y)127.21%
Cap/Sales(3y)8.59%
Cap/Sales(5y)5.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.31%
EPS Next Y78.98%
EPS Next 2Y37.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.49%
Revenue growth 3Y1.83%
Revenue growth 5Y29.5%
Sales Q2Q%16.93%
Revenue Next Year8.72%
Revenue Next 2Y17.05%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.96%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.69%
OCF growth 3YN/A
OCF growth 5YN/A